We are at a hinge moment in the biopharmaceutical industry, where we are seeing profound changes in drug discovery and development powered by the union of technology and biotechnology. At Amgen we have been preparing for this moment for over a decade, investing in the power of artificial intelligence (AI), data science and other technologies to create the next generation of medicines that will bring the most value to patients.
What is generative biology?
Generative biology reimagines the protein drug discovery and design process by using AI and machine learning-powered computational models.
FEATURING:
Marissa Mock
Director of the Generative Biology group at Amgen
